High levels of maternally derived RSV-neutralizing antibodies correlate with a decreased risk of infection and hospitalization in newborn infants. G protein is a 90-kDa, highly glycosylated ...

Currently, three approved vaccines against this virus are available: the adjuvanted RSV prefusion F protein-based vaccine ... limited subgroup analyses (e.g., by frailty). The study measured ...

Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary ...

The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a ... Novavax said the FDA ...

Good evening and welcome to the Dyadic International First Quarter 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared ...

designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.